In general, IDH1/2 mutations are less frequent in AML patients with activating FLT3 mutations, CEBPA mutations, and are largely absent in patients with AML associated with recurrent chromosomal abnormalities, such as t(15;17), t(8;21), inv(16) (Chou et al., 2010, 2011b; Patel et al., 2011a). The gene discussed is IDH1; the disease is acute myeloid leukemia.